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Espectroscopia por ressonância magnética no diagnóstico do câncer de próstata: experiência
inicial
Homero José de Farias e Melo1, Denis Szejnfeld2, Cristiano Silveira Paiva3, Nitamar Abdala4,
Homero Oliveira de Arruda5, Suzan Menasce Goldman6, Jacob Szejnfeld7
OBJECTIVE: To report an experiment involving the introduction of a protocol utilizing commercially available
three-dimensional 1H magnetic resonance spectroscopy imaging (3D 1H MRSI) method in patients diagnosed
with prostatic tumors under suspicion of neoplasm. MATERIALS AND METHODS: Forty-one patients in the
age range between 51 and 80 years (mean, 67 years) were prospectively evaluated. The patients were divided
into two groups: patients with one or more biopsies negative for cancer and high specific-prostatic antigen
levels (group A), and patients with cancer confirmed by biopsy (group B). The determination of the target-
area (group A) or the known cancer extent (group B) was based on magnetic resonance imaging and MRSI
studies. RESULTS: The specificity of MRSI in the diagnosis of prostate cancer was lower than the specificity
reported in the literature (about 47%). On the other hand, for tumor staging, it corresponded to the specificity
reported in the literature. CONCLUSION: The introduction and standardization of 3D 1H MRSI has allowed
the obtention of a presumable diagnosis of prostate cancer, by a combined analysis of magnetic resonance
imaging and metabolic data from 3D 1H MRSI.
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OBJETIVO: Demonstrar a experiência na implantação de um protocolo de espectroscopia por ressonância
magnética do 1H tridimensional (3D 1H MRSI), disponível comercialmente, aplicando-o em pacientes com
suspeita de neoplasia prostática e com diagnóstico estabelecido de tumor prostático. MATERIAIS E MÉTO-
DOS: Estudo realizado de forma prospectiva, em 41 pacientes com idades entre 51 e 80 anos (média de 67
anos). Dois grupos foram formados: pacientes com uma ou mais biópsias negativas para câncer e antígeno
prostático específico elevado (grupo A) e pacientes com câncer confirmado por biópsia (grupo B). Procurou-
-se, a partir dos resultados da ressonância magnética e espectroscopia por ressonância magnética, determi-
nar a área-alvo (grupo A) ou a extensão do câncer conhecido (grupo B). RESULTADOS: No diagnóstico de
câncer de próstata a espectroscopia por ressonância magnética apresentou especificidade abaixo da descrita
pela literatura, cerca de 47%. Já para o estadiamento do tumor diagnosticado, houve correspondência com
a literatura. CONCLUSÃO: A implantação e padronização da espectroscopia por ressonância magnética per-
mitiram a obtenção de informações importantes para o diagnóstico presuntivo da existência de câncer de
próstata, combinando as imagens por ressonância magnética com os dados metabólicos da espectroscopia
por ressonância magnética.
Unitermos: Espectroscopia por ressonância magnética; Próstata; Neoplasia prostática.
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alone, has transformed this disease not only
into an important medical problem, but also
into a public health and socioeconomic(1,2)
one. In Brazil, 49,530 new cases are esti-
mated in 2008, according to Instituto
Nacional de Câncer(3).
However, in spite of the fact that digi-
tal rectal examination is considered as the
first diagnostic tool, it is limited as it pre-
sents negative results for non palpable nod-
ules (T1c stage)(4).
The uncertainty with respect to the up-
per limit value for cancer screening with
prostate specific antigen (PSA) and its low
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INTRODUCTION
The increase in the incidence of prostate
cancer from 86,000 cases in 1985 to
218,890 cases in 2007 in the United States
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specificity contribute for two current clini-
cal challenges: only one in four men with
PSA > 4 ng/ml actually present cancer at
biopsy, and approximately one third of the
prostate cancers are detected in men with
normal PSA(5).
Ultrasonography is widely utilized be-
cause of its relatively low cost, and when
used with the transrectal probe this method
offers the best opportunity to guide the
gland biopsy(6,7) . However it is limited to
local staging due to the difficulty in the
early diagnosis of the extracapsular extent
and high operator dependency, which lim-
its the reproducibility of the technique(8,9)
Amongst the other radiological tech-
niques, magnetic resonance imaging (MRI)
is the most useful diagnostic tool for evalu-
ation of tumor stages, mainly on cases
where endorectal coil is utilized(8) . Mag-
netic resonance imaging has a significantly
higher sensitivity (51–89%) in the detec-
tion of the tumor when compared with
transrectal ultrasonography (TRUS) (27–
86%). However, both methods present a
low specificity (58–94%)(8,9).
Recently, magnetic resonance spectros-
copy (MRS) brought a new diagnostic
hope. Based on anatomical data generated
by MRI, this method can demonstrate the
metabolic indicators detected in the pros-
tate gland, enhancing the accuracy in the
probable localization of the tumor(8,10–14).
In Brazil, there are still only few MRI cen-
ters with the technical background required
to perform prostate examinations with
spectroscopy. Additionally, this technique
is not covered by health insurance plans or
by the Sistema Único de Saúde (SUS) (Bra-
zilian Public Health System).
With the real perspective of a significant
improvement in prostate cancer diagnosis
utilizing MRSI, a protocol for the acquisi-
tion of spectroscopic data was imple-
mented at the Department of Imaging Di-
agnosis – Universidade Federal de São
Paulo/Escola Paulista de Medicina (Uni-
fesp/EPM).
MATERIALS AND METHODS
The present prospective study was de-
veloped between February of 2004 and
December of 2005, with 41 male patients
with ages ranging from 51 to 80 years, and
mean age of 67 years, selected by the
Nucleus of Prostate Research (Nuppro) of
Unifesp/EPM. Throughout this period,
Nuppro assisted approximately 2,000 pa-
tients.
The patients were divided into two
groups: group A – patients with clinic-labo-
ratory diagnostic suspicion of cancer, in-
cluding 28 patients selected due to the fact
that they had one or more negative biopsies,
and persistently high PSA levels and/or
altered digital prostate examination results;
group B – patients with confirmed diagno-
sis of prostate cancer, including 13 patients
selected due to the fact of having positive
biopsies (one Gleason 3, one Gleason 5,
three Gleason 6, six Gleason 7, two
Gleason 8).
The patients from group A with diag-
nostic suspicion presented indication for
prostate biopsies because of persistently
high PSA levels. For these patients, MRSI
was performed in order to identify the pos-
sible altered areas to be approached at US
guided biopsy.
In the case of Group B patients, besides
the identification of tumor site,
locoregional staging of the prostate cancer
was performed by MRI. Patients included
in this group were not submitted to biopsy
after MRSI, as the previously performed
biopsies were positive.
This study protocol was previously sub-
mitted to and approved by the Committee
for Ethics in Research of Unifesp/EPM. All
patients signed a term of free and informed
consent.
Examination protocol
Preparation and positioning of the patient
The patients preparation for examina-
tion consisted of four-hour fasting and in-
travenous administration of antispasmodic
drug. No intestinal lavage was performed.
All patients were previously instructed on
the examination procedures.
The endorectal coil introduction was
performed with the patient in left lateral
decubitus. The coil characteristics indicate
that the blue line on its shaft should be
positioned towards the ventral direction in
relation to the patient, and the first portion
of the shaft should be positioned at the
level of the anal border. The extremity of
the endorectal coil was protected with an
unlubricated condom externally lubricated
with Xylocaine® gel. Then, the balloon at
the end of the coil was inflated with 100 ml
of air to distend the rectum wall, keeping
the safety support to avoid displacement of
the coil and loss of the condom. After
completion of this operation, the patient
was slowly positioned in dorsal decubitus,
holding the coil shaft.
The positioning consisted in connecting
endorectal, phased-array and column coils
(SP’s), with the objective of optimizing the
image acquisition and spectroscopy.
With these maneuvers, the patient re-
mained in dorsal decubitus, with the feet
entering the equipment first, and with the
arms towards the floor. Finally, the patient
was asked to remain still during the whole
examination process, breathing normally,
and without contracting the rectal channel.
Exam technique
Protocol for magnetic resonance image
acquisition
All examinations were performed in a
1.5 T Magnetom Sonata unit with a gradi-
ent of 43 mT/m (Siemens Medical Systems;
Erlangen, Germany), at the Department of
Imaging Diagnosis of Unifesp/EPM.
The radiofrequency body coil, present
in the equipment itself, was utilized for
excitation, the endorectal coil, combined
with the matrix coil, in the prepubic region
of the patient; the SP’s, located in the pre-
sacral region of the patient, were utilized
for MR signal reception.
The MRI examination programming
was performed as recommended in the lit-
erature, as demonstrated on Figure 1. Chart
1 includes a summary of the sequence pa-
rameters applied.
In the sagittal plane, the positioning was
performed following the longest axis of the
prostate, aligning the pubic symphysis with
the lumbar spine. In the coronal plane, the
block was angled according to the longest
axis of the prostate. In the axial plane, the
angle was according to the longest prostate
axis, in such a manner to position the im-
ages from the pubic symphysis to the end
of the seminal vesicles.
Paramagnetic contrast injection (10 ml)
was systematically performed in the pa-
tients, after spectroscopy, on T1-weighted
sequences with fat saturation.
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Protocol for spectroscopic data acquisition
A multiple-volume system was utilized
in the selection of the spectroscopic vol-
ume of interest, acquired by the commer-
cially available sequence PRESS CSI 3D
hybrid (TR 1,300 ms/TE 120 ms; FOV 60–
100 cm2; voxel 0.10–0.22 cm3, 4–5 acqui-
sitions) (Siemens Medical Systems;
Erlangen, Germany), so as to minimize
possible artifacts of the periprostatic struc-
tures.
The MRSI programming included T2-
weighted sequences so as to evaluate the
whole prostatic volume as shown on Fig-
ure 2. Besides being freely angled, without
any limitations for the spectroscopic acqui-
sition, the MRSI sequence offered the pos-
sibility of using eight external saturation
bars, thus minimizing the effects of the non
homogenization of the field by the effect
of magnetic susceptibility, originated from
the air within the coil, bone structures,
periprostatic fat, and presence of urine in
the bladder and in the penile urethra.
For the prostate spectroscopy, spectral
suppression was utilized both for water and
fat, according to recommended in litera-
ture(8,10–13,15–18) , making it possible for the
lipids present in the prostate, not to inter-
fere in the acquisition.
The total examination time, including
the patients positioning, MR image and
spectroscopic data acquisition, was ap-
proximately 45 minutes.
Image and spectroscopic data analysis
The studies were consensually evalu-
ated by two observers with regards to the
morphology, and by one observer with re-
spect to the spectral analysis.
The first phase consisted of the se-
quences analysis for evaluation of the pros-
tate morphology, areas of signal alteration
(peripheral zone and transition zone), iden-
Chart 1 MRI sequence parameters utilized in the protocol.
Sequence
Axial T2 FSE
Coronal T2 FSE
Sagittal T2 FSE
Axial T1 FSE
Axial FS Gd
No. of images
24
16
19
24
24
Thickness (mm)
3.0
3.0
3.0
3.0
3.0
TR (ms)
3,000–3,900
3,000–3,900
3,200–4,200
500–650
500–650
TE (ms)
94–100
94–100
94–100
12–14
12–14
Matrix
480 × 512
512 × 512
512 × 512
464 × 512
464 × 512
FSE, fast spin echo; FS, fat saturation.
Figure 1. Programming of MRI of prostate. Programming representation in the axial, coronal, and sagittal planes.
Figure 2. Model of prostate MRSI programming. Utilization of the three orthogonal planes with free multi-voxel angulation and eight saturation bars positioned
in such a way to minimize artifacts.
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tification of possible blood residues, evalu-
ation of periprostatic fat and seminal
vesicle integrity.
The second phase consisted of the
analysis of spectroscopy acquisition. The
postprocessing was made in a Leonardo®
workstation (Siemens Medical Systems;
Erlangen, Germany). The spectroscopic
data were measured after baseline correc-
tion, of the chemical deviation, with water
as reference and T2-weighted in the three
orthogonal planes to evaluate the position-
ing of the voxel. The Fourier transforma-
tion was prioritized in three spatial direc-
tions, applying the Hamming filter.
The whole prostatic volume was quali-
tatively evaluated. Initially, the regions of
interest were identified as those that pre-
sented an increase in choline levels and
decreased citrate levels, therefore nomi-
nated target areas. Then a qualitative and
quantitative evaluation was performed,
identifying the relationship between me-
tabolite peak amplitude ratios target area.
Upon conclusion of the two phases, the
analyses results were compared in consen-
sus and classified into three groups: 1 –
areas detected by MRI in agreement with
MRSI; 2 – areas detected by MRI in dis-
agreement with MRSI; 3 – areas not de-
tected by MRI but characterized by MRSI.
Biopsy of the target area
Based on MRI and MRSI results,
TRUS-guided biopsies were performed in
the Ultrasonography Sector of the Depart-
ment of Imaging Diagnosis at Unifesp/
EPM, utilizing a Philips SD 800 unit
(Philips Medical Systems; Eindhoven, The
Netherlands) and 18 G needle.
The radiologists were informed on the
position of the target areas according to the
McNeal’s nomenclature(19). In patients with
no suspect areas at MRI and MRSI, ran-
domized biopsies were performed obtain-
ing 18 fragments.
Statistical analysis
A descriptive study was developed, con-
sidering the small number of patients. Even
with this limitation, one tried to demon-
strate the most relevant findings by asso-
ciation measurements (sensitivity, specific-
ity, accuracy, positive predictive value and
negative predictive value).
RESULTS
In relation to alterations identified at
MRSI and /or MRI, compared with biop-
sies after MRSI in the 28 patients included
in group A (high PSA levels and negative
biopsies), 12 presented alterations both at
MRI and MRSI , 8 only at MRSI , in 7 no
alteration was observed, and in one, alter-
ation was observed only at MRI.
In group A, the relationship between
citrate/choline ratio (positive: 0.221 ± 0.166;
negative: 1.441 ± 0.562) and (choline +
creatine)/citrate ratio (positive: 7.922 ±
4.976; negative: 2.151 ± 1.089) amplitudes
was established. These data were measured
in a systematic manner, utilizing the same
analysis protocol in the target area of all the
patients included in the present study.
In the group A, for patients with alter-
ations both at MRI and MRSI, presented
100% sensitivity, 47% specificity, 58%
accuracy, 37% positive predictive value,
and 100% negative predictive value (Fig-
ure 3).
All of the 13 patients from group B pre-
sented alterations both at MRI and MRSI.
Citrate/choline ratio (mean: 0.369 ±
0.231) and (choline+creatine)/citrate ratio
(mean: 5.471 ± 4.355) amplitudes of group
B were measured in a systematic manner,
with the same analysis protocol, in the area
affected by cancer of all the patients in-
cluded in the present study.
For the group B, sensitivity, specificity,
accuracy, positive predictive value and
negative predictive value were 100%.
DISCUSSION
Prostate cancer screening fundamentals
are based on the fact that patients diag-
nosed at screening tend to present a more
favorable stage as compared with those
clinically diagnosed, with a possible de-
crease in the rate of specific mortality due
to prostate cancer.
Magnetic resonance imaging is com-
monly utilized for the tumor staging after
a diagnosis is established by prostatic bi-
opsy. When the disease is confined to the
prostate, the capsule will appear intact,
even if there is an extensive contact or regu-
lar bulging between the capsule and the
tumor(8,20).
Additionally, MRI can also demonstrate
the prostate anatomy, identifying areas with
alteration of signal intensity, which may
represent focal lesions in the gland. Thus,
this method provides an extensive evalua-
tion of patients with prostate cancer, for its
capacity of observation of the primary dis-
ease and locoregional lymph nodes in-
volvement(20,21). On T1-weighted images,
the prostate appearance is homogeneous
with isosignal, and the zonal anatomy and
intraprostatic diseases are not demon-
strated. These are observed on T2-weighted
images, as the cancer presents itself as an
area with signal hypointensity at peripheral
zone, which is hyperintense(21).
Technical advances for better signal
detection by MRI antennas, have led to the
development of endorectal coils(22). Mag-
netic resonance imaging endorectal coil
presents > 97% accuracy in the localization
of known prostate lesions; however, the
method performance is poor in the detec-
tion of focal tumors with < 5 mm in diam-
eter(23).
Magnetic resonance spectroscopy of the
prostate increases the diagnostic probabil-
ity in cases of cancer, by adding metabolic
data on the gland to the morphological in-
formation. The sensitivity of this method
ranges from 68% to 95% and specificity,
from 70% to 91%(21,24).
Advantages of the utilization of this
technique in the determination of prostate
cancer include: accurate spectral localiza-
tion of each small morphologically abnor-
mal region; precise correlation between the
spectral mapping and the high-resolution
magnetic resonance imaging; evaluation of
the abnormal metabolism extent; three-di-
mensional coverage of the entire gland(17).
A variation is observed when MRI re-
sults and MRSI metabolic data are com-
bined. Together, they result in 56–94% sen-
sitivity and 70–98% specificity(10,24,25).
In 2004, Yuen et al.(26) observed that
MRI data in association with those of
MRSI, presented 100% sensitivity and
70.3% specificity in the determination of
suspicious areas.
Most recently, in 2005, Prando et al.(27)
observed that MRI combined with MRSI
presented high sensitivity (84% to 100%)
and low specificity (44% to 71%) in the
identification of target areas.
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In the present study, alterations at MRI
or at MRSI alone presented very low
specificity. Thus, the findings should be
considered when both peripheral zone
hypointense signal at MRI and metabolic
inversions at MRSI are present (58%
accuracy).
As regards sensitivity of MRI in asso-
ciation with MRSI in the detection of pro-
static cancer (group A), the results of the
present study are in agreement with previ-
ous studies. However, with respect to
specificity, the results were below (47%)
those described in the literature, and agree-
ing only with Prando et al.(27), including in
what refers to the group in study.
Therefore, information detected by
MRSI with respect to the probable local-
ization of prostate cancer may be useful in
the programming of TRTRUS-guided bi-
opsies, particularly in patients with PSA
levels indicating cancer and with previous
negative biopsies. It can also improve the
stratification of patients in clinical screen-
ing, and also their monitoring, from a
simple clinical follow up to a minimally
aggressive treatment(17).
The study protocol implementation un-
derwent several phases.  The first one oc-
curred in 2004, with the installation of the
Magneton Sonata MRI in the Department
of Imaging Diagnosis, where commercially
available Siemens MRI and spectroscopy
pulse sequences were adapted to the work-
ing conditions.
The second phase of prostate MRSI pro-
tocol set up corresponded to the elaboration
of spectral analysis criteria. Based on these
criteria, spectral data analysis was stan-
dardized, involving both qualitative and
quantitative studies adapted according to
recommendations in the literature(8,10–13,15–
18,21,24–27,28)
. Additionally, efforts were made
to standardize studies reports and the
TRTRUS-guided biopsies programming
based on MRI and MRSI data.
However, these phases were modified
to better adapt to diagnosis requirements,
not to mention the aspect of one being at
the beginning of the learning curve. The
valuation of certain metabolic inversions in
the first patients contributed to the fact that
accuracy results of the method fell short of
the literature ones, approximately 58%.
This difficulty in the diagnosis may be
explained by the fact that MRSI as well as
MRI results may be influenced by inflam-
matory processes (prostatitis), postbiopsy
hemorrhages, and by several types of treat-
ments such as hormone therapy, radio-
therapy, cryotherapy among others(21,25,29).
Concerning the mathematical relation,
our study demonstrated that the utilization
of creatine must be better evaluated, veri-
fying to what extent its amplitude is being
influenced by choline and spermidines. This
was demonstrated by the higher number of
false-positive results, with the mathemati-
cal relation (choline + creatine)/citrate.
CONCLUSION
The implantation and standardization of
magnetic resonance spectroscopy imaging
allowed the acquisition of relevant data for
Figure 3. MRSI graph (A) and MR images (B) of a
72-year-old patient from group A, with alterations
at MRI and MRSI, diagnosed with prostate cancer
after TRUS-guided biopsy (clinical stage T2a,
Gleason 6 and PSA of 2.5 ng/dl). A: Spectrum of
the voxel of interest with high choline peak level and
decreased citrate peak level. B: T2-weighted images
in the three orthogonal planes showing the target
area voxel. AT MRI, the peripheral zone presented
a diffusely heterogeneous signal, with some ill-de-
fined nodular areas. Signs of periprostatic signal
alteration are observed, suggesting capsule inva-
sion, besides signs of seminal vesicle invasion, more
evident to the right.
A B
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the presumptive diagnosis of the presence
of prostate cancer, combining the MR im-
ages with metabolic data from MRSI.
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